Claudiani, Simone, Janssen, Jeroen JWM, Byrne, Jenny, Smith, Graeme, Blijlevens, Nicole, Raghavan, Manoj, Smith, Matthew, Clark, Richard E 
ORCID: 0000-0002-1261-3299, Mclain-Smith, Susan, Carter, Angela M et al (show 2 more authors)
(2022)
A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands.
EUROPEAN JOURNAL OF HAEMATOLOGY, 109 (1).
pp. 90-99.
|
PDF
A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid le.pdf - Published version Download (1MB) | Preview |
Abstract
<h4>Objectives</h4>To describe the real-world effectiveness and safety of bosutinib in patients with chronic myeloid leukemia (CML).<h4>Methods</h4>This was a multi-center, retrospective, non-interventional chart review study conducted in 10 hospitals in the United Kingdom and the Netherlands.<h4>Results</h4>Eighty-seven patients were included. Bosutinib was the third-line tyrosine kinase inhibitor (TKI) in 33 (38%) and fourth-line in 44 (51%) patients. Median treatment duration was 15.6 months. Among 84 patients in chronic phase (CP) at baseline, 26 (31%) switched to bosutinib due to resistance and 57 (68%) due to intolerance to prior TKIs. Cumulative complete cytogenetic and major molecular response rates in CP patients were 67% and 55%, respectively. After a median follow-up of 21.5 months, nine (11%) patients in CP died; estimated overall survival rates at 1 and 2 years postbosutinib initiation were 95% and 91%, respectively. Overall, 33/87 (38%) patients discontinued bosutinib due to either lack of efficacy/disease progression (17%), adverse events (14%), death (2%), or other reasons (5%). Eighty-two (94%) patients experienced ≥1 adverse event possibly related to bosutinib, most commonly diarrhea (52%).<h4>Conclusions</h4>Bosutinib used in routine clinical practice in heavily pretreated patients with CML is an effective treatment for patients in CP and is generally tolerable.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | bosutinib, chronic myeloid leukemia, retrospective studies, tyrosine kinase inhibitor |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 17 Oct 2022 15:51 |
| Last Modified: | 18 Jan 2023 20:36 |
| DOI: | 10.1111/ejh.13775 |
| Open Access URL: | https://doi.org/10.1111/ejh.13775 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3165563 |
Dimensions
Dimensions
